| Literature DB >> 12773048 |
Susumu Mitsumori1, Tatsuo Tsuri, Tsunetoshi Honma, Yoshiharu Hiramatsu, Toshihiko Okada, Hiroshi Hashizume, Shiro Kida, Masanao Inagaki, Akinori Arimura, Kiyoshi Yasui, Fujio Asanuma, Junji Kishino, Mitsuaki Ohtani.
Abstract
In an earlier paper, we reported that novel prostaglandin D(2) (PGD(2)) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD(2) receptor antagonists having the 6,6-dimethylbicyclo[3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD(2) receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12773048 DOI: 10.1021/jm0205189
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446